Contact

All Stories

  1. Patient and healthcare professional perspectives on which potential prognostic factors for failure of total elbow replacement should be investigated

    Article • Journal of Orthopaedic Surgery and Research, August 2025, Springer Science + Business Media

    Dr. Lianne Kearsley-Fleet

  2. Death in young people with Juvenile Idiopathic Arthritis (JIA) is exceedingly rare

    Article • EULAR Rheumatology Open, June 2025, Elsevier

    Dr. Lianne Kearsley-Fleet

  3. Incidence of major adverse cardiovascular events in patients with rheumatoid arthritis treated with Janus kinase inhibitors compared to biologic disease‐modifying antirheumatic drugs: data from an international collaboration of registries (the "JA...

    Article • Arthritis & Rheumatology, April 2025, Wiley

    Dr. Lianne Kearsley-Fleet

  4. Annals of the Rheumatic Diseases Collection on juvenile idiopathic arthritis (JIA) 2019-2024

    Article • Annals of the Rheumatic Diseases, February 2025, Elsevier

    Dr. Lianne Kearsley-Fleet

  5. Total elbow arthroplasty in England

    Article • The Bone & Joint Journal, November 2024, Bone & Joint

    Dr. Lianne Kearsley-Fleet

  6. Role of rheumatoid arthritis registries worldwide: What have they taught us?

    Article • Best Practice & Research Clinical Rheumatology, October 2024, Elsevier

    Dr. Lianne Kearsley-Fleet

  7. Association between body weight and tocilizumab effectiveness in rheumatoid arthritis: results from the BSRBR-RA

    Article • Rheumatology, September 2024, Oxford University Press (OUP)

    Dr. Lianne Kearsley-Fleet

  8. Total elbow replacement in England: a protocol for analysis of National Joint Registry and Hospital Episode Statistics data

    Article • Journal of Orthopaedic Surgery and Research, August 2024, Springer Science + Business Media

    Dr. Lianne Kearsley-Fleet

  9. What happens if you switch from originator to biosimilar therapy in JIA?

    Article • The Lancet Rheumatology, June 2024, Elsevier

    Dr. Lianne Kearsley-Fleet

  10. Potential impact of European Medicines Agency measures to minimise risk of serious side effects on JAKi prescribing and utilisation in the UK

    Article • Rheumatology, May 2024, Oxford University Press (OUP)

    Dr. Lianne Kearsley-Fleet

  11. Prognostic factors associated with failure of total elbow arthroplasty

    Article • Bone and Joint Research, May 2024, Bone & Joint

    Dr. Lianne Kearsley-Fleet

  12. Comparative effectiveness of a second TNF inhibitor versus a non‐TNF biologic in the treatment of polyarticular course juvenile idiopathic arthritis

    Article • Arthritis Care & Research, March 2024, Wiley

    Dr. Lianne Kearsley-Fleet

  13. Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the ‘JAK-pot’ study)

    Article • Annals of the Rheumatic Diseases, December 2023, BMJ

    Dr. Lianne Kearsley-Fleet

  14. Evaluation of serious infections, including Mycobacterium tuberculosis, during treatment with biologic disease-modifying antirheumatic drugs: does line of therapy matter?

    Article • Rheumatology, September 2023, Oxford University Press (OUP)

    Dr. Lianne Kearsley-Fleet

  15. Switching from the original etanercept to a biosimilar for RA: just as good as the originator.

    Article • Rheumatology, September 2023, Oxford University Press (OUP)

    Dr. Lianne Kearsley-Fleet

  16. Impact of Risk Factors on COVID‐19 Outcomes in Unvaccinated People with Rheumatic Diseases

    Article • Arthritis Care & Research, August 2023, Wiley

    Dr. Lianne Kearsley-Fleet, Charlie Rapple (Kudos)

  17. Prognostic factors associated with failure of total elbow replacement: a protocol for a systematic review

    Article • BMJ Open, August 2023, BMJ

    Dr. Lianne Kearsley-Fleet

  18. Socioeconomic deprivation is associated with reduced response and lower treatment persistence with TNF inhibitors in rheumatoid arthritis

    Article • Rheumatology, June 2023, Oxford University Press (OUP)

    Dr. Lianne Kearsley-Fleet

  19. Starting a biologic for the first time – are biosimilars truly ‘similar’?

    Article • Rheumatology, March 2023, Oxford University Press (OUP)

    Dr. Lianne Kearsley-Fleet

  20. Association Between Race/Ethnicity and COVID ‐19 Outcomes in Systemic Lupus Erythematosus ( SLE ) Patients from the United States: Data from the COVID ...

    Article • Arthritis Care & Research, October 2022, Wiley

    Dr. Lianne Kearsley-Fleet

  21. Continuing specialist care into adulthood in young people with juvenile idiopathic arthritis: a retrospective cohort study using electronic health records in England

    Article • Rheumatology, September 2022, Oxford University Press (OUP)

    Dr. Lianne Kearsley-Fleet

  22. If you stop biologic therapy for remission, are you likely to remain off treatment?

    Article • Rheumatology, September 2022, Oxford University Press (OUP)

    Dr. Lianne Kearsley-Fleet

  23. Development and external validation of a model predicting new‐onset chronic uveitis at different disease durations in juvenile idiopathic arthritis

    Article • Arthritis & Rheumatology, August 2022, Wiley

    Dr. Lianne Kearsley-Fleet

  24. Development of a Prediction Model for COVID ‐19 Acute Respiratory Distress Syndrome in Patients With Rheumatic Diseases: Results From the Global Rheumatology Alliance Registry

    Article • ACR Open Rheumatology, July 2022, Wiley

    Dr. Lianne Kearsley-Fleet

  25. Environmental and societal factors associated with COVID-19-related death in people with rheumatic disease: an observational study

    Article • The Lancet Rheumatology, July 2022, Elsevier

    Dr. Lianne Kearsley-Fleet

  26. JAK-pot collaboration: comparing how well advanced therapies work in patients with RA

    Article • Annals of the Rheumatic Diseases, June 2022, BMJ

    Dr. Lianne Kearsley-Fleet

  27. Effectiveness of sequential biologic and targeted disease modifying anti-rheumatic drugs for rheumatoid arthritis

    Article • Rheumatology, March 2022, Oxford University Press (OUP)

    Dr. Lianne Kearsley-Fleet

  28. Children and young people with arthritis are not at high risk of severe COVID-19.

    Article • Annals of the Rheumatic Diseases, March 2022, BMJ

    Dr. Lianne Kearsley-Fleet

  29. Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance

    Article • Annals of the Rheumatic Diseases, February 2022, BMJ

    Dr. Lianne Kearsley-Fleet

  30. Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry

    Article • Annals of the Rheumatic Diseases, December 2021, BMJ

    Dr. Lianne Kearsley-Fleet

  31. Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study

    Article • The Lancet Rheumatology, November 2021, Elsevier

    Dr. Lianne Kearsley-Fleet

  32. Children and young people with arthritis… What other diseases do they have?

    Article • Rheumatology, October 2021, Oxford University Press (OUP)

    Dr. Lianne Kearsley-Fleet

  33. Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry

    Article • Annals of the Rheumatic Diseases, May 2021, BMJ

    Dr. Lianne Kearsley-Fleet

  34. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry

    Article • Annals of the Rheumatic Diseases, January 2021, BMJ

    Dr. Lianne Kearsley-Fleet

  35. Understanding Refractory Rheumatoid Arthritis: Implications for a Therapeutic Approach

    Article • Drugs, May 2020, Springer Science + Business Media

    Dr. Lianne Kearsley-Fleet

  36. Which biologic drugs are used, and how well do they work, in children and young people with JIA

    Article • The Lancet Rheumatology, March 2020, Elsevier

    Dr. Lianne Kearsley-Fleet

  37. Risk of uveitis in patients with JIA receiving etanercept: challenges of analysing real-world data

    Article • Rheumatology, October 2019, Oxford University Press (OUP)

    Dr. Lianne Kearsley-Fleet

  38. Cervical screening attendance and results for women with rheumatoid arthritis in England

    Article • Rheumatology, August 2019, Oxford University Press (OUP)

    Dr. Lianne Kearsley-Fleet

  39. Moderate disease does not necessarily mean moderate disability

    Article • PLOS One, May 2019, PLOS

    Dr. Lianne Kearsley-Fleet

  40. Methotrexate remains an effective treatment for JIA, although nausea is common

    Article • Rheumatology, March 2019, Oxford University Press (OUP)

    Dr. Lianne Kearsley-Fleet

  41. Use and effectiveness of rituximab in children and young people with JIA

    Article • Rheumatology, October 2018, Oxford University Press (OUP)

    Dr. Lianne Kearsley-Fleet

  42. Improved disease activity in patients with systemic JIA treated with tocilizumab or anakinra

    Article • Rheumatology, August 2018, Oxford University Press (OUP)

    Dr. Lianne Kearsley-Fleet

  43. Cancers and deaths in patients with severe psoriatic arthritis on TNF-inhibitor treatment.

    Article • Rheumatology, August 2018, Oxford University Press (OUP)

    Dr. Lianne Kearsley-Fleet

  44. Identifying treatment refractory disease in people with rheumatoid arthritis

    Article • Annals of the Rheumatic Diseases, July 2018, BMJ

    Dr. Lianne Kearsley-Fleet

  45. Long-term rituximab treatment in patients with rheumatoid arthritis

    Article • Rheumatology, March 2018, Oxford University Press (OUP)

    Dr. Lianne Kearsley-Fleet

  46. TNF inhibitors and dementia in patients with rheumatoid arthritis

    Article • International Journal of Geriatric Psychiatry, February 2018, Wiley

    Dr. Lianne Kearsley-Fleet

  47. Long-term TNF-inhibitor treatment in patients with psoriatic arthritis

    Article • RMD Open, January 2018, BMJ

    Dr. Lianne Kearsley-Fleet

  48. How common is remission in juvenile idiopathic arthritis?

    Article • Seminars in Arthritis and Rheumatism, December 2017, Elsevier

    Dr. Lianne Kearsley-Fleet

  49. Patterns of height growth in patients with juvenile idiopathic arthritis.

    Article • Seminars in Arthritis and Rheumatism, November 2017, Elsevier

    Dr. Lianne Kearsley-Fleet

  50. Registries and cohort studies around the world in juvenile idiopathic arthritis.

    Article • Pediatric Rheumatology, April 2017, Springer Science + Business Media

    Dr. Lianne Kearsley-Fleet

  51. Effect of Rituximab on pregnancy outcome in women with Rheumatoid Arthritis

    Article • Rheumatology, January 2017, Oxford University Press (OUP)

    Dr. Lianne Kearsley-Fleet

  52. Lupus and vasculitis‐like events in patients with rheumatoid arthritis treated with TNFi therapy

    Article • RMD Open, January 2017, BMJ

    Dr. Lianne Kearsley-Fleet

  53. Tocilizumab in patients with rheumatoid arthritis in the United Kingdom

    Article • Clinical Rheumatology, December 2016, Springer Science + Business Media

    Dr. Lianne Kearsley-Fleet

  54. Mortality in juvenile idiopathic arthritis - increased in systemic juvenile idiopathic arthritis.

    Article • Archives of Disease in Childhood, October 2016, BMJ

    Dr. Lianne Kearsley-Fleet

  55. Adults with Juvenile Idiopathic Arthritis on TNFi therapy in the United Kingdom.

    Article • RMD Open, October 2016, BMJ

    Dr. Lianne Kearsley-Fleet

  56. Cancer in patients with RA receiving TNF inhibitors or rituximab with prior malignancy

    Article • Rheumatology, August 2016, Oxford University Press (OUP)

    Dr. Lianne Kearsley-Fleet

  57. Risk of pneumonia infection in patients with rheumatoid arthritis treated with TNFis

    Article • Rheumatology, April 2016, Oxford University Press (OUP)

    Dr. Lianne Kearsley-Fleet

  58. Choice of biologics for children with juvenile idiopathic arthritis in the United Kingdom.

    Article • Rheumatology, January 2016, Oxford University Press (OUP)

    Dr. Lianne Kearsley-Fleet

  59. One year of treatment with etanercept (Enbrel) in children with juvenile idiopathic arthritis

    Article • Rheumatology, December 2015, Oxford University Press (OUP)

    Dr. Lianne Kearsley-Fleet

  60. Discovery of recent swine infectious agents.

    Article • Veterinary Research, September 2015, Springer Science + Business Media

    Dr. Lianne Kearsley-Fleet

  61. Infections in children with juvenile idiopathic arthritis treated with etanercept.

    Article • Arthritis & Rheumatology, August 2015, Wiley

    Dr. Lianne Kearsley-Fleet

  62. Height change in children with juvenile idiopathic arthritis after two years of etanercept (Enbrel).

    Article • Rheumatology, January 2015, Oxford University Press (OUP)

    Dr. Lianne Kearsley-Fleet

  63. Comparing patients with Rheumatoid Arthritis in European biologic registers

    Article • Rheumatology, November 2014, Oxford University Press (OUP)

    Dr. Lianne Kearsley-Fleet

  64. Canine epilepsy in the UK - how common is it and which dogs are at risk?

    Article • Veterinary Record, January 2013, BMJ

    Dr. Lianne Kearsley-Fleet